shr-1314
mAbexperimental
Clinical trial activity
19 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
5
Phase 4
1
Earliest trial started Aug 1, 2016 (NCT02934412)
Timeline
Indications
Studied for
- Arthritis, Psoriatic · Phase 3
- Axial Spondyloarthritis · Phase 1
- Graves Disease · Phase 2
- Lupus Erythematosus, Systemic · Phase 1
- Lupus Nephritis · Phase 2
- Pharmacokinetics · Phase 1
- Psoriasis · Phase 4
- Small Cell Lung Carcinoma · Phase 2
- Spondylitis, Ankylosing · Phase 2/Phase 3
- Therapeutic Equivalency · Phase 1
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298102 ↗
Also known as
- shr-1314
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07069270 | Phase 2 | Sep 1, 2025 | Fujian Medical University |
| NCT06881290 | Phase 1 | May 19, 2025 | Chinese SLE Treatment And Research Group |
| NCT06860750 | Phase 3 | Apr 29, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06779097 | Phase 4 | Feb 28, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06833307 | Phase 3 | Feb 28, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06640257 | Phase 3 | Nov 4, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06182384 | Phase 1 | Dec 31, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05394857 | Phase 2 | Jun 13, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05055934 | Phase 2 | Oct 22, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04924296 | Phase 2 | Jun 28, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04840485 | Phase 2/Phase 3 (Phase 3) | Jun 9, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04839016 | Phase 3 | Apr 25, 2021 | Hengrui Therapeutics, Inc. |
| NCT04527484 | Phase 1 | Aug 20, 2020 | Hengrui Therapeutics, Inc. |
| NCT04326881 | Phase 1 | Apr 7, 2020 | Hengrui Therapeutics, Inc. |
| NCT04121143 | Phase 2 | Oct 30, 2019 | Hengrui Therapeutics, Inc. |
| NCT03710681 | Phase 1 | Aug 2, 2018 | Hengrui Therapeutics, Inc. |
| NCT03704428 | Phase 1 | Apr 1, 2018 | Hengrui Therapeutics, Inc., People's Liberation Army of China, Soochow University |
| NCT03463187 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2017 | Hengrui Therapeutics, Inc. |
| NCT02934412 | Phase 1 | Aug 1, 2016 | Atridia Pty Ltd., University of Adelaide |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 9 | 9 | 4 | 2021 |
| Hengrui Therapeutics, Inc. | For profit | 7 | 7 | 3 | 2017 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Chinese SLE Treatment And Research Group | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2018 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Adelaide | Academic/Hospital | 1 | 0 | 1 | 2016 |
8 organizations
Page 1 / 1